Monday at #ASCO2024: Niraparib + XRT Phase 0/2 in Newly Diagnosed, MGMT-Unmethylated GBM OS= 20.3 months #Gliofocus Study coming in June: a global, label-enabling, Ivy Brain Tumor Center-sponsored, head-to-head Phase 3 trial in partnership with GSK

40% response rate for chemo +pembro in advanced penile cancer #ASCO24 HPV16-positive (cORR 55.6%) and TMB-high (cORR 75%) potentially enrich. Great investigator initiated study from LACOG and Fernando Maluf 

Pay it forward and help all future residents by filling this out!

Game-changing! 👏🏻👏🏻 Kudos to the SARC and the investigators!

When something unfathomable happens to one of our own, we should come together and support 💜 Please consider donating for Muhammad and his 3-month old daughter. gofund.me/d6460eb4

🙏🏽

Hi Percy - thank you for the nice comments and all you do for ASTRO and our field!

From JAMA: USPSTF recommends all women undergo routine #breastcancer screening every other year beginning at age 40, an update from the 2016 recommendation to start at age 50. ja.ma/45mG9BB

Nice study and prominent result in The Lancet. It's not every day that radiotherapy gets a new indication. RCT of SBRT for neovascular age related macular degeneration. #radonc

Six practice changing trials till date in cervical cancer till date . ESMO - Eur. Oncology #esmogynae24

Whaat a game!! Champions #ICCMensT20WorldCup2024 😍

🚨PRODIGE23🚨 Long term results now published! T3-4 rectal adenocarcinoma Randomized: CRT➡️🔪➡️FOLFOX mFOLFIRINOX ➡️ CRT➡️🔪➡️FOLFOX ✅✅✅Improved OS!!! Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS pubmed.ncbi.nlm.nih.gov/38986769/

Alright friends- I like the "inclusive" algorithm as it acknowledges suitable options with flexibility to balance nuance and most importantly, patient preferences. But... I was asked what I prefer. By request- here is my more limited decision pathway- open to feedback 🙂🤓

#Match2025 applicants - Please join current #radonc residents UPMC Hillman Cancer Center for a virtual open house on Sept. 18! Register now at forms.office.com/r/7qK3Y2QeVF Heath Skinner, MD PhD Parul Barry Uzoma K. Iheagwara, MD, PhD Ria Mulherkar, MD ARRO

Keynote 867, which investigated Pembrolizumab in stage I and II NSCLC after SBRT, was closed early due to futility. ➡️This underscores the critical need for phase 3 trials, as promising phase 2 results do not always translate into clinical benefit in phase 3

September is Gynecologic Cancer Awareness Month!💜 #RadOnc #GynOnc #MedOnc work together to provide comprehensive care to patients with gyn cancers. Let’s raise awareness to screening, treatment, & survivorship in cervical, endometrial, vulvar, vaginal, & ovarian cancers! #gyncsm

Join us today for this very important webinar! Matthew Harkenrider, MD Idalid "Ivy" Franco MD MPH William Small Jr. BhanuPrasad Venkatesulu John A Vargo Heath Skinner, MD PhD UPMC Hillman Cancer Center Magee-Womens Research Institute & Foundation #GCSM Awareness Month

Important take home message ➡️ two thirds of patients, REFRACTORY to standard tx, experienced pain relief from liver mets or HCC after just a SINGLE fraction. RT is non-invasive and with this regimen would typically only require 2 outpatient visits. thelancet.com/journals/lanon…

A valuable series during gyn cancer awareness month! Join us! UPMC Hillman Cancer Center BhanuPrasad Venkatesulu John A Vargo Heath Skinner, MD PhD Susannah Ellsworth UPMC Rad Onc Residency

Top notch! ARRO ACROresident ARS ROCKET🚀 Shearwood McClelland III, M.D.